Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06062706
Other study ID # RAC 2121012
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date August 6, 2023
Est. completion date October 30, 2023

Study information

Verified date September 2023
Source King Faisal Specialist Hospital & Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This will be a study to examine the outcomes of open, laparoscopic, and robotic Living Donor Liver Transplantation (LDLT) procedures. The analysis will encompass 3,448 cases (1,724 donor-recipient pairs) from January 2011 to March 2023, documenting the transition between these surgical techniques, with a noted crossover in 2018.


Description:

Background: Liver transplantation is a primary treatment for end-stage liver disease, enhancing survival rates and life quality. Living donor liver transplantation (LDLT) has gained prominence due to the scarcity of deceased donor organs. Historically, the open technique dominated living donor hepatectomies. However, advances in minimally invasive surgery (MIS) led to laparoscopic and later robotic procedures. With the introduction of robotic surgery, MIS for complex surgeries improved, offering better precision and ergonomics. Objective: To compare the short and long-term outcomes of open, laparoscopic, and robotic LDLT, focusing on both donors and recipients. Methods: Study Design: Retrospective analysis of data from a prospective liver transplant registry, examining three LDLT techniques. Setting: King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. Participants: All consecutive living donor and recipient pairs undergoing LDLT between January 2011 and March 2023. Exclusions include dual or domino LDLT. Surgical Techniques: Open, laparoscopic, and robotic techniques used for donor hepatectomies. Variables: Primary focus on morbidity, conversion rates, and in-hospital mortality for both donors and recipients. Secondary variables will include major complications, graft, and recipient survival rates. Data Sources and Measurement: Data sourced from a secured, encrypted transplant database, detailing patient data, operation characteristics, and post-op outcomes. Complication severity will be captured using the Clavien-Dindo classification and Comprehensive Complication Index™. Study Size: Determined by the total number of procedures during the study duration, deemed sufficient for comparison. Quantitative Variables: Demographics, comorbidities, operational details, post-op and long-term outcomes. Statistical Methods: Various statistical tests will be employed for comparison, including the Student t, Mann-Whitney U, one-way ANOVA, Fischer and Chi square. Survival will be evaluated using the Kaplan-Meier method. Multivariable binary logistic regression will be employed. All statistical analyses will be conducted using R. Ethics Approval: Obtained (ID: RAC 2121012) and in accordance with the 1964 Helsinki declaration.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 3448
Est. completion date October 30, 2023
Est. primary completion date October 15, 2023
Accepts healthy volunteers No
Gender All
Age group 1 Month to 75 Years
Eligibility Inclusion Criteria: - All donor and recipient pairs that underwent LDLT at the study institution - Between 01 January 2011 to 31 March 2023 - Both adult-to-adult and adult-to-pediatric LDLT are included. Exclusion Criteria: - Dual and domino LDLT are excluded.

Study Design


Intervention

Procedure:
Donor hepatectomy
Donor hepatectomy is a surgical procedure to resect a portion of the liver from a living donor for transplantation. This usually involved the right lobe, the left lobe or the left lateral section of the liver. Depending on the surgical method, this can be achieved through open, laparoscopic, or robotic-assisted techniques. As for the recipient, liver transplantation involves a total hepatectomy of the diseased liver from the recipient and implantation of the liver graft from the donor. This is typically performed using the open surgical approach.

Locations

Country Name City State
Saudi Arabia Organ Transplant Center of Excellence, King Faisal Specialist Hospital & Research Centre Riyadh

Sponsors (1)

Lead Sponsor Collaborator
King Faisal Specialist Hospital & Research Center

Country where clinical trial is conducted

Saudi Arabia, 

Outcome

Type Measure Description Time frame Safety issue
Other Major morbidity rates These include complications of Grade > 2 according to the Clavien-Dindo Classification, i.e., requiring an intervention on the patient requiring organ support in the Intensive Care Unit From date of operation until the date of hospital discharge assessed up to 90 days postoperatively.
Other Specific complication rates Infection, bleeding, ascites, vascular, and biliary complications From date of operation until the date of hospital discharge assessed up to 90 days postoperatively.
Primary Donor overall morbidity rate Complication rate of any severity according to the Clavien-Dindo Classification From date of donor hepatectomy until the date of first hospital discharge assessed up to 90 days postoperatively.
Primary Recipient overall morbidity rate Complication rate of any severity according to the Clavien-Dindo Classification From date of liver transplantation until the date of hospital discharge assessed up to 90 days postoperatively.
Primary Recipient in-hospital mortality rate Recipient death up to 90 days of follow up From date of liver transplantation until the date of death assessed up to 90 days post-transplant.
Secondary Donor minimally invasive surgery conversion to open rate Includes conversion to open surgery for both laparoscopic and robotic approaches. This does not apply for the open surgical approach. Time from operation start until conversion to open in minutes assessed up to 720 min
Secondary Donor hospital stay in days Number of days the donor was hospitalised during first hospitalisation. Does not include re-hospitalizations. From date of donor hepatectomy until the date of first hospital discharge assessed up to 90 days postoperatively.
Secondary Recipient Intensive Care Unit (ICU) stay in days Total number of days recipient stayed in ICU. This included readmissions to ICU. Total number of days hospitalised in ICU, from date of liver transplant until the date of discharge from ICU assessed up to 90 days postoperatively.
Secondary Recipient hospital stay in days Number of days the recipient was hospitalised. Does not include rehospitalizations. From date of liver transplant until the date of first hospital discharge assessed up to 90 days postoperatively.
Secondary Graft survival rates Graft survival defined as re-transplantation or recipient death. From date of liver transplantation until the date of re-transplantation or recipient death or last follow up assessed up to 120 months post-transplant
Secondary Recipient survival rates Recipient survival defined as death post-transplant From date of liver transplantation until the date of recipient death or last follow up assessed up to 120 months post-transplant
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2